Valuation: NEOVACS

Market Cap 4.09K 4.69K 3.85K 3.51K 6.58K 449K 6.58K 46.12K 17.78K 229K 17.62K 17.23K 739K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -231K -189K -172K -323K -22.08M -324K -2.27M -874K -11.25M -866K -847K -36.3M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 day-15.06%
1 week-26.67%
Current month-45.00%
1 month-67.65%
3 months-89.00%
6 months-97.56%
Current year-99.75%
1 week 0.22
Extreme 0.22
0.27
1 month 0.22
Extreme 0.22
0.66
Current year 0.22
Extreme 0.22
267
1 year 0.22
Extreme 0.22
4,200
3 years 0.22
Extreme 0.22
32,000,000
5 years 0.22
Extreme 0.22
351,920,000
10 years 0.22
Extreme 0.22
351,920,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Date Insider Type Main position Quantity % Market Cap. Importance
2/27/21 A Sell

Chief Executive Officer

2,505,144 1.3796%
2/23/21 A Sell

Chief Executive Officer

6,391,053 3.5196%
2/23/21 A Sell

Chief Executive Officer

1,108,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
-15.06%-26.67%-99.99%-100.00% 47.24K
+0.59%+3.31%+1.03%+24.53% 46.28B
+1.30%+3.10%+44.15%+31.38% 43.85B
+0.95%-5.40%+342.72%+548.37% 40.93B
+4.23%+5.53%+9.35%+89.62% 39.89B
+1.11%+1.80%+11.52%+43.15% 29.5B
+1.94%+6.24%+25.19%+145.07% 17.09B
+0.37%-9.84% - - 15.55B
+2.12%+10.41%+24.78%+39.05% 15.22B
+0.24%+32.23%-11.57% - 14.05B
Average -0.20%+2.21%+38.57%+102.65% 26.24B
Weighted average by Cap. +1.59%+2.08%+70.37%+141.24%

Financials

2023 2024
Net sales 533K 612K 502K 458K 858K 58.61M 859K 6.02M 2.32M 29.86M 2.3M 2.25M 96.34M 434K 498K 409K 372K 698K 47.68M 699K 4.89M 1.89M 24.29M 1.87M 1.83M 78.38M
Net income -8.74M -10.03M -8.23M -7.5M -14.06M -961M -14.08M -98.62M -38.01M -489M -37.67M -36.83M -1.58B -32.91M -37.75M -31M -28.23M -52.93M -3.62B -53M -371M -143M -1.84B -142M -139M -5.94B
Net Debt -237K -271K -223K -203K -380K -25.99M -381K -2.67M -1.03M -13.24M -1.02M -996K -42.72M -205K -235K -193K -176K -330K -22.53M -330K -2.31M -892K -11.48M -884K -864K -37.04M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
21/09/26 0.2200 -15.06% 48,050
18/09/26 €0.2590 +3.60% 21,445
17/09/26 €0.2500 +0.81% 48,245
16/09/26 €0.2480 -4.62% 24,259
15/09/26 €0.2600 -7.14% 43,488
  1. Stock Market
  2. Stocks
  3. ALNEV Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!